Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use (MHRA release November 2018)

Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight and UV rays and to use adequate sun protection.

Further information can be found in the MHRA Drug Safety Update